Clinical trials: Cervix, Dysplasia
Uterine Cervical Neoplasms
Imaging the Uterine Cervix - UltraSightHD™
The purpose of this study is to investigate the performance ability of the UltraSightHD™. The instrument will be assessed on characteristics such as focus quality, ability to image the entire cervix, and illumination.
- Trial name
- NCT01090635
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- STI-Medical Systems
Papillomavirus Infections
Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.
The purpose of this study was to evaluate efficacy of 851B gel over a range of concentrations and dosing regimens on high-risk cervical human papillomavirus infection in women.
- Trial name
- NCT00312286
- Testing
- 851B
- Where
- 93 sites in United States, Canada and 1 more
- Volunteers
- 538 people
- Sponsor
- Takeda
Atypical Squamous Cell of Undetermined Significance, ASC-US
Comparison Of Cytology And Molecular Screening For Detecting Cervical Reactive Cellular Changes In General Population
This study compares the efficacy of cytology (Pap smear) with the molecular screening in their ability to detect reactive cellular changes in the cervix among an open population
- Conditions
- Atypical Squamous Cell of Undetermined Significance, ASC-US, Atypical Glandular Cells of Uncertain Significance, AGUS
- Trial name
- NCT07211204
- Testing
- Physical examination, Liquid-based cytology, Molecular screening
- Where
- Mexico
- Volunteers
- healthy volunteers welcome
- Sponsor
- Timser SAPI de CV
Cervical Intraepithelial Neoplasia
Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity PEK Fusion Protein Vaccine
Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity of a Three Dose Regimen of Escalating Doses of PEK Fusion Protein Vaccine in Women with LSIL or HSIL.
- Trial name
- NCT01880411
- Testing
- PEK Fusion Protein Vaccine
- Volunteers
- 15 people
- Sponsor
- HealthBanks Biotech Co., Ltd.
Cervical Intraepithelial Neoplasia 3
Safety of GX-188E DNA Therapeutic Vaccine Administered by Electroporation to Cervical Intraepithelial Neoplasia Grade 3
This study is to determine maximum tolerable dose (MTD) of GX 188E by defining the safety profile the safety and maximum tolerated dose of GX-188E administered by electroporation in Cervical Intraepithelial Neoplasia grade 3 (CIN…
- Trial name
- CIN3 (NCT01634503)
- Testing
- GX-188E administered by electroporation
- Where
- South Korea
- Volunteers
- 9 people
- Sponsor
- Genexine, Inc.
Cervical Intraepithelial Neoplasia
Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)
The purpose of this study is to access the efficacy and safety of GX-188E according the protocol in patients with Cervical Intraepithelial Neoplasia 2, 2/3 or 3 (CIN3)
- Trial name
- NCT02596243
- Testing
- GX-188E
- Where
- 16 sites in Estonia, South Korea and 1 more
- Volunteers
- 134 people
- Sponsor
- Genexine, Inc.
Cervical Cancer, Vulvar Cancer
Long-term Follow-up of Bivalent Human Papillomavirus (HPV) Vaccine Study in Women
This extension study aims to evaluate the long-term protection and immune response of the bivalent HPV vaccine in women aged 18-30 who participated in a previous efficacy study (311-HPV-1003).
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN - Cervical Intraepithelial Neoplasia
- Trial name
- NCT06776055
- Testing
- HPV-16/18 vaccine
- Where
- 9 sites in China
- Volunteers
- 5,372 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Papillomavirus Infections
Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.
The purpose of this study was to evaluate efficacy of 851B gel over a range of concentrations and dosing regimens on high-risk cervical human papillomavirus infection in women.
- Trial name
- NCT00117884
- Testing
- 851B
- Where
- 23 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- Takeda
Cervical Intraepithelial Neoplasia
Safety Study to Test the Safety of HspE7 and Poly-ICLC Given in Patients With Cervical Intraepithelial Neoplasia
The purpose of this study is to determine the safety and tolerability of HspE7 and Poly-ICLC when given together
- Trial name
- NCT00493545
- Testing
- HspE7 and Poly-ICLC
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Nventa Biopharmaceuticals Corporation
Cervical Intraepithelial Neoplasia
Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia
The purpose of this study is to determine the optimal dose of GX-188E for the Phase 3 and access the efficacy and safety of GX-188E according the protocol in patients with Cervical Intraepithelial Neoplasia 3 (CIN3).
- Trial name
- NCT02139267
- Testing
- GX-188E
- Where
- 4 sites in South Korea
- Volunteers
- 72 people
- Sponsor
- Genexine, Inc.
Carcinoma, Neoplasia; Intraepithelial, Cervix
Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions
Phase II clinical trial, monocentric, not controlled, in patients with high grade cervical intraepithelial lesions. A total of 62 patients with a diagnosis of CIN II, III or carcinoma in situ will be included.
- Conditions
- Carcinoma, Neoplasia; Intraepithelial, Cervix, Glandular Neoplasms, Epithelial Neoplasm
- Trial name
- NCT03549273
- Testing
- Glizigen® + Ocoxin-Viusid®
- Where
- Cuba
- Volunteers
- 62 people
- Sponsor
- Catalysis SL
Uterine Cervical Neoplasms, Cervix Intraepithelial Neoplasia
Safety and Tolerability of Cidofovir Gel Applied on Cervix Squamous Lesions
Human Papilloma Virus (HPV) infections induce cervical intraepithelial neoplasia (CIN) of cervix. To reduce incidence of invasive tumor associated with high grade CIN lesions, the standard treatment is the conisation of cervix…
- Trial name
- NCT00989443
- Testing
- Cidofovir gel
- Where
- Belgium
- Volunteers
- 6 people
- Sponsor
- Mithra Pharmaceuticals
Cervical Intraepithelial Neoplasia
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
Cervical cancer is associated with Human Papilloma Virus. About 57% of cervical cancer is the result of infection by Human Papilloma Virus strain 16 (HPV-16). HPV is a very common virus that can affect the cells of the cervix.
- Trial name
- ADXS11-001 (NCT01116245)
- Testing
- ADXS11-001 (Lm-LLO-E7)
- Where
- 15 sites in United States
- Volunteers
- 81 people
- Sponsor
- Advaxis, Inc.
Cervical Intraepithelial Neoplasia
Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) of Cervical Intraepithelial Neoplasia (CIN) Grade 1
The study will examine the effect of HAL vs placebo photodynamic therapy of low-grade cervical precancerous lesions (dysplasia) in women.
- Trial name
- NCT00708942
- Testing
- Hexaminolevulinate (HAL)
- Where
- 5 sites in France, Germany and 1 more
- Volunteers
- 83 people
- Sponsor
- Photocure
Cervical Intraepithelial Neoplasia
Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia
An effective and safe medical therapy would be most welcome to reduce the need for surgical interventions and related adverse events and psychological impact on patients with cervical cancer precursors.
- Trial name
- NCT01256424
- Testing
- HAL 5% with illumination, HAL 1% with illumination, HAL 0.2% with illumination
- Where
- 2 sites in Germany, Norway
- Volunteers
- 262 people
- Sponsor
- Photocure
Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion
REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
HPV-301 is a prospective, randomized, double-blind, placebo controlled Phase 3 study to determine the efficacy, safety, and tolerability of VGX-3100 administered by intramuscular (IM) injection followed by electroporation (EP)…
- Conditions
- Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
- Trial name
- REVEAL 1 (NCT03185013)
- Testing
- VGX-3100, Electroporation (EP)
- Where
- 60 sites in United States, Argentina and 17 more
- Volunteers
- 201 people
- Sponsor
- Inovio Pharmaceuticals
Cervical Intraepithelial Neoplasia
A Post Marketing Surveillance (PMS) Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Female Chinese Subjects
The purpose of this prospective, multi-centre, PMS cohort study was to monitor the safety of Cervarix, which is the first HPV vaccine licensed for use in China, to help prevent cervical cancer caused by HPV types 16 and 18.
- Trial name
- NCT03438006
- Testing
- Safety data collection (following routine vaccination)
- Where
- 7 sites in China
- Volunteers
- 3,016 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Intraepithelial Neoplasia 3
Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation
This study is to follow up on the change of immune response by measuring HPV type 16/18 E6 and E7 specific T cell response and lesion condition in subjects who have administered in DNA-based therapeutic vaccine.
- Trial name
- GX-188E (NCT02411019)
- Testing
- GX-188E
- Where
- South Korea
- Volunteers
- 67 people
- Sponsor
- Genexine, Inc.
Cervical Intraepithelial Neoplasia
A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Intraepithelial Neoplasia
This is an open-label study to evaluate the safety, tolerability, and efficacy of ABI-2280 in participants with cervical squamous intraepithelial lesions. This study is divided into 2 parts - Part A and Part B.
- Trial name
- NCT05502367
- Testing
- ABI-2280 Vaginal Tablet/Insert
- Where
- 7 sites in Australia, Peru and 1 more
- Volunteers
- 44 people
- Sponsor
- Antiva Biosciences
Cervical Intraepithelial Neoplasia
Meta-analysis of Efficacy of Topotecan
This meta-analysis was conducted to investigate the efficacy of Topotecan and other treatments for recurrent and stage IVB carcinoma of the cervix
- Trial name
- NCT01160185
- Testing
- paclitaxel, cisplatin, topotecan
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline